ZA200402123B - Medicine for preventing and treating bromidrosis. - Google Patents
Medicine for preventing and treating bromidrosis. Download PDFInfo
- Publication number
- ZA200402123B ZA200402123B ZA200302123A ZA200402123A ZA200402123B ZA 200402123 B ZA200402123 B ZA 200402123B ZA 200302123 A ZA200302123 A ZA 200302123A ZA 200402123 A ZA200402123 A ZA 200402123A ZA 200402123 B ZA200402123 B ZA 200402123B
- Authority
- ZA
- South Africa
- Prior art keywords
- odour
- body odour
- botulinus toxin
- botulinus
- toxin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 title 1
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 39
- 239000003053 toxin Substances 0.000 claims description 30
- 231100000765 toxin Toxicity 0.000 claims description 30
- 208000035985 Body Odor Diseases 0.000 claims description 9
- 206010055000 Bromhidrosis Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 description 26
- 210000004243 sweat Anatomy 0.000 description 12
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 208000008454 Hyperhidrosis Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 6
- 101710182532 Toxin a Proteins 0.000 description 6
- 230000037315 hyperhidrosis Effects 0.000 description 6
- 210000001104 scent gland Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000035943 smell Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002781 deodorant agent Substances 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108030001720 Bontoxilysin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940089093 botox Drugs 0.000 description 3
- 229940053031 botulinum toxin Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940098753 dysport Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- -1 fragrants Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000028684 sweat gland disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10146647A DE10146647A1 (de) | 2001-09-21 | 2001-09-21 | Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402123B true ZA200402123B (en) | 2004-10-04 |
Family
ID=7699852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200302123A ZA200402123B (en) | 2001-09-21 | 2004-03-17 | Medicine for preventing and treating bromidrosis. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050036966A1 (enExample) |
| EP (2) | EP1427385B1 (enExample) |
| JP (1) | JP4966478B2 (enExample) |
| KR (1) | KR100796243B1 (enExample) |
| CN (1) | CN1289061C (enExample) |
| AU (1) | AU2002349268B2 (enExample) |
| CA (1) | CA2461117C (enExample) |
| DE (1) | DE10146647A1 (enExample) |
| EA (2) | EA011988B1 (enExample) |
| HU (1) | HU230398B1 (enExample) |
| IL (2) | IL160875A0 (enExample) |
| MX (1) | MXPA04002614A (enExample) |
| PL (1) | PL209639B1 (enExample) |
| UA (1) | UA78718C2 (enExample) |
| WO (1) | WO2003026602A2 (enExample) |
| ZA (1) | ZA200402123B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113349A1 (en) | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
| US7288259B2 (en) | 2002-08-19 | 2007-10-30 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| BRPI0408114A (pt) | 2003-03-06 | 2006-03-01 | Botulinum Toxin Res Ass Inc | tratamento de calázio crÈnico e hordéolo com toxina botulinìca |
| US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| EP2494958A1 (en) | 2006-12-01 | 2012-09-05 | Anterios, Inc. | Amphiphilic Entity Nanoparticles |
| KR20160130519A (ko) * | 2008-06-26 | 2016-11-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| US8454975B1 (en) * | 2010-01-11 | 2013-06-04 | Elizabeth VanderVeer | Method for enhancing skin appearance |
| US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| US11191819B2 (en) | 2018-08-28 | 2021-12-07 | Ira Sanders | Skin therapeutics |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19852981A1 (de) * | 1998-11-17 | 2000-05-18 | Martin Schmidt | Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen |
| US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
| US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
-
2001
- 2001-09-21 DE DE10146647A patent/DE10146647A1/de not_active Ceased
-
2002
- 2002-09-23 UA UA20040402705A patent/UA78718C2/uk unknown
- 2002-09-23 JP JP2003530240A patent/JP4966478B2/ja not_active Expired - Lifetime
- 2002-09-23 EA EA200601238A patent/EA011988B1/ru unknown
- 2002-09-23 WO PCT/DE2002/003561 patent/WO2003026602A2/de not_active Ceased
- 2002-09-23 EA EA200400436A patent/EA008146B1/ru unknown
- 2002-09-23 CA CA002461117A patent/CA2461117C/en not_active Expired - Lifetime
- 2002-09-23 KR KR1020047004120A patent/KR100796243B1/ko not_active Expired - Fee Related
- 2002-09-23 AU AU2002349268A patent/AU2002349268B2/en not_active Ceased
- 2002-09-23 MX MXPA04002614A patent/MXPA04002614A/es active IP Right Grant
- 2002-09-23 EP EP02781099.3A patent/EP1427385B1/de not_active Expired - Lifetime
- 2002-09-23 PL PL373528A patent/PL209639B1/pl unknown
- 2002-09-23 IL IL16087502A patent/IL160875A0/xx unknown
- 2002-09-23 EP EP15179974.9A patent/EP2987483B1/de not_active Expired - Lifetime
- 2002-09-23 CN CNB028185765A patent/CN1289061C/zh not_active Expired - Fee Related
- 2002-09-23 HU HU0401913A patent/HU230398B1/hu not_active IP Right Cessation
- 2002-09-23 US US10/490,244 patent/US20050036966A1/en not_active Abandoned
-
2004
- 2004-03-15 IL IL160875A patent/IL160875A/en active IP Right Grant
- 2004-03-17 ZA ZA200302123A patent/ZA200402123B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2987483B1 (de) | 2020-12-02 |
| DE10146647A1 (de) | 2003-04-24 |
| EA008146B1 (ru) | 2007-04-27 |
| HUP0401913A2 (hu) | 2005-01-28 |
| WO2003026602A3 (de) | 2003-08-28 |
| JP2005507888A (ja) | 2005-03-24 |
| CN1556693A (zh) | 2004-12-22 |
| PL373528A1 (en) | 2005-09-05 |
| EA200601238A1 (ru) | 2007-06-29 |
| PL209639B1 (pl) | 2011-09-30 |
| UA78718C2 (en) | 2007-04-25 |
| EP2987483A1 (de) | 2016-02-24 |
| JP4966478B2 (ja) | 2012-07-04 |
| AU2002349268B2 (en) | 2007-12-13 |
| EP1427385B1 (de) | 2015-09-23 |
| US20050036966A1 (en) | 2005-02-17 |
| IL160875A0 (en) | 2004-08-31 |
| MXPA04002614A (es) | 2005-02-17 |
| EP1427385A2 (de) | 2004-06-16 |
| CN1289061C (zh) | 2006-12-13 |
| WO2003026602A2 (de) | 2003-04-03 |
| IL160875A (en) | 2010-11-30 |
| EA011988B1 (ru) | 2009-06-30 |
| KR100796243B1 (ko) | 2008-01-21 |
| KR20040048895A (ko) | 2004-06-10 |
| EA200400436A1 (ru) | 2007-02-27 |
| CA2461117A1 (en) | 2003-04-03 |
| CA2461117C (en) | 2009-12-08 |
| HUP0401913A3 (en) | 2008-02-28 |
| HU230398B1 (hu) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2461117C (en) | Botulinus toxin for treatment of body odour | |
| US6635263B2 (en) | Beauty method | |
| US5972321A (en) | Acid neutralization of skin | |
| WO2011119247A2 (en) | Topical skincare composition | |
| Koblenzer et al. | Chronic cutaneous dysesthesia syndrome: A psychotic phenomenon or a depressive symptom? | |
| Ballantyne et al. | Dermal sensitizing potential of glutaraldehyde: a review and recent observations | |
| EP4011359A1 (en) | Topical cosmetic composition, use of the composition and serum for facial application | |
| Eedy et al. | Olfactory facial hyperhydrosis responding to amitriptylene | |
| CN111093611A (zh) | 用于在治疗或预防体味时应用的短杆菌素及其制剂 | |
| US20220287953A1 (en) | Topical cosmetic composition, use of the composition and tonic for facial application | |
| Pessemier et al. | Underarm body odor, the microbiome, and probiotic treatment | |
| KR102211761B1 (ko) | 미네랄 복합체를 포함하는 체취 억제용 화장료 조성물 및 이의 제조방법 | |
| Rothman | Drugs in cosmetics | |
| WO2023161504A1 (en) | Use of botulinum toxin for reduction of skin pore size and sebum production | |
| KR20250097997A (ko) | 분리 2제형 화장료 조성물 | |
| Raab | Aromatherapy in the intensive care unit: An overview | |
| KR20220103600A (ko) | 각질 박리 또는 피부 상태 개선용 조성물 | |
| JP2022183707A (ja) | 皮膚常在菌叢制御用組成物 | |
| RAY | Reveal The Beauty Secrets | |
| Waterman et al. | PSA: Unpleasant odours: Under odours | |
| Bodokh | Hyperhidrosis and other dermatologic indications | |
| Bailey | Stress Sweat v Regular Sweat; Why it smells worse and how to manage it | |
| CN1875942A (zh) | 抑汗、除臭外用喷雾剂配方 |